Filip Josephson M.D., Ph.D. (b 1970) is a clinical assessor at the Swedish Medical Products Agency (MPA), where his primary focus is the regulatory assessment of antiviral agents. He is the rapporteur for the ongoing revision of the European Medicines Agency EMA/CHMP guidelines on the clinical evaluation of medicinal products for the treatment of chronic hepatitis C, which are presently available for consultation at the EMA webpage (www.ema.europa.eu). He is also the representative of EMA/CHMP at the Forum for Collaborative HIV Research and a member of the Swedish Reference Group for Antiviral Therapy (RAV). Dr Josephson graduated from the Karolinska Institute Medical School, Stockholm, Sweden, in 1997. After a few years of clinical work, mainly within the discipline of Internal Medicine, he specialized in Clinical Pharmacology, and for several years was the pharmacology consultant at the HIV policlinics of Stockholm, Sweden. In 2008 he started working at the Swedish MPA. In 2009 he defended his thesis entitled “Studies on the Clinical Pharmacology of Antiretroviral Agents” at the Karolinska Institute.
